Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.48% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
876
Wabtec
WAB
$50.3B
| $25.5M | 0.02% |
+328,195
| New | +$24.3M |
|
|
ACHN
877
DELISTED
Achillion Pharmaceuticals
ACHN
| $25.5M | 0.02% |
4,231,600
+379,000
| +10% | +$2.19M |
|
878
Welltower
WELL
$169B
| $25.4M | 0.02% |
310,760
-278,201
| -47% | -$23.8M |
|
879
Buckle
BKE
$2.31B
| $25.3M | 0.02% |
936,450
+158,600
| +20% | +$3.77M |
|
880
First American
FAF
$7.56B
| $25.3M | 0.02% |
433,400
+244,900
| +130% | +$15M |
|
881
Utah Medical Products
UTMD
$230M
| $25.3M | 0.02% |
234,214
-3,300
| -1% | -$334K |
|
882
PTC
PTC
$16.7B
| $25.2M | 0.02% |
+336,700
| New | +$24M |
|
|
CVA
883
DELISTED
Covanta Holding Corporation
CVA
| $25.1M | 0.02% |
1,693,361
+238,961
| +16% | +$3.64M |
|
|
GLDD
884
DELISTED
Great Lakes Dredge & Dock
GLDD
| $25M | 0.02% |
2,209,101
+183,800
| +9% | +$1.96M |
|
885
Quanex
NX
$981M
| $24.9M | 0.02% |
1,460,207
+407,407
| +39% | +$7.67M |
|
886
Pediatrix Medical
MD
$2.14B
| $24.9M | 0.02% |
896,670
+171,370
| +24% | +$4.3M |
|
887
Vishay Intertechnology
VSH
$5.11B
| $24.9M | 0.02% |
1,170,013
-684,000
| -37% | -$13.3M |
|
|
PFC
888
DELISTED
Premier Financial Corp. Common Stock
PFC
| $24.9M | 0.02% |
789,700
-49,700
| -6% | -$1.5M |
|
889
Carnival Corporation Ltd
CCL
$38.9B
| $24.9M | 0.02% |
489,100
-964,100
| -66% | -$43.1M |
|
890
News Corp Class B
NWS
$17.8B
| $24.8M | 0.02% |
1,710,053
+314,153
| +23% | +$4.33M |
|
891
Global Net Lease
GNL
$1.9B
| $24.8M | 0.02% |
1,222,595
-223,003
| -15% | -$4.4M |
|
|
PLAN
892
DELISTED
Anaplan, Inc.
PLAN
| $24.8M | 0.02% |
473,100
+417,514
| +751% | +$20.7M |
|
893
Cheniere Energy
LNG
$55B
| $24.8M | 0.02% |
405,888
-892,660
| -69% | -$54.9M |
|
894
Exelon
EXC
$47B
| $24.7M | 0.02% |
761,006
-975,825
| -56% | -$31.6M |
|
|
AMAG
895
DELISTED
AMAG Pharmaceuticals
AMAG
| $24.7M | 0.02% |
2,030,200
-4,000
| -0.2% | -$43.7K |
|
896
Silicon Laboratories
SLAB
$7.28B
| $24.7M | 0.02% |
212,898
+159,200
| +296% | +$17.5M |
|
897
Park Aerospace
PKE
$811M
| $24.7M | 0.02% |
1,517,397
-7,300
| -0.5% | -$121K |
|
898
Hudbay
HBM
$11.8B
| $24.7M | 0.02% |
5,945,809
+790,000
| +15% | +$2.86M |
|
|
AD
899
Array Digital Infrastructure
AD
$3.09B
| $24.6M | 0.02% |
679,662
-4,500
| -0.7% | -$158K |
|
900
TechTarget
TTGT
$277M
| $24.6M | 0.02% |
940,800
+144,800
| +18% | +$3.67M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.